Vaginal rejuvenation is a category label covering four treatments, not one procedure. You do not need to arrive knowing which is yours.
Book a consultationAsk which one fits
Vaginal rejuvenation is an umbrella term for treatments aimed at dryness, laxity or appearance. No energy-based device is FDA-cleared or approved for this use, and the FDA issued a safety communication about that marketing in 2018. Prescription therapy for menopausal vaginal atrophy carries approved indications; platelet injection for these symptoms does not.
If the phrase has felt slippery, that is not you. Underneath it is usually one concern: dryness, pain with sex, laxity, leaking, appearance. Bring that, not the term. No energy-based device is FDA-cleared for this use, so the useful place to start is the symptom.
Nothing here tightens tissue on the spot. Platelet-rich plasma is your own blood, spun to concentrate platelets, then injected into the anterior vaginal wall. This use is not approved or cleared by the FDA, and the preparation systems are cleared to produce platelet concentrate rather than for this indication. Energy devices heat tissue instead. In 2018 the FDA stated that no such device is cleared for vaginal rejuvenation, and described reports of burns, scarring and chronic pain. Vaginal estrogen and prasterone, both vaginal inserts, and ospemifene, an oral tablet that acts on estrogen receptors, carry approved indications for menopausal vaginal atrophy and painful sex, along with the largest evidence base in this category. Their labels carry boxed warnings, which your prescriber goes through before anything is written.
| Option | What it is | U.S. regulatory status for this use | Typical downtime | Evidence base |
|---|---|---|---|---|
| Platelet-rich plasma injection | Your own concentrated platelets, injected into the anterior vaginal wall and clitoral region | Not FDA-approved for this use; autologous preparation | 0 to 2 days | Small, mostly uncontrolled series |
| Platelet-rich fibrin (PRF) | Your own platelets in a fibrin matrix, spun without anticoagulant, slower release | Not FDA-cleared for this use; autologous preparation | 0 to 2 days | Smaller than platelet-rich plasma; largely extrapolated |
| Hyaluronic acid filler | Gel placed in the labia majora for volume, dissolvable with hyaluronidase | Off-label placement of an FDA-approved facial filler | 2 to 7 days of swelling or bruising | Case series and practice reporting |
| Energy-based devices (CO2, Er:YAG, radiofrequency) | Heat applied to vaginal tissue to provoke a wound-healing response | No device is FDA-cleared for this indication; FDA safety communication issued 2018 | 1 to 3 days typically claimed | Mixed; sham-controlled trials have been largely negative |
| Prescription therapy (vaginal estrogen, prasterone, ospemifene) | Topical or oral treatment for menopausal vaginal atrophy and painful sex | FDA-approved indications, with boxed warnings on the labels | None | Randomized controlled trials |
Four different things sit under one phrase, so here they are side by side: what each does to the tissue, and where each stands with the FDA. What decides is the complaint underneath: dryness, volume, laxity or leaking. Ranges reflect product labeling, published series and practice observation.
Autologous platelet-rich plasma injection for female intimate health — Autologous. This use is not FDA-approved, the preparation systems are cleared only to produce platelet concentrate, and the published evidence is small and largely uncontrolled. The treatment is described here generically, as a platelet-rich plasma injection, rather than under the licensed protocol name patients often search for.
Platelet-rich fibrin (PRF) — Autologous and not cleared for this use. The fibrin matrix releases growth factors more slowly than platelet-rich plasma, which is the measurable difference between the two preparations.
Hyaluronic acid filler (Juvéderm®, Restylane®) — Off-label placement of hyaluronic acid fillers approved for facial injection. Covered in full on its own page, priced per syringe, and dissolvable with hyaluronidase.
Topical and buffered lidocaine — Standard compounded or commercial topical anesthetic. Dose and contact time are limited; allergy history is checked at the examination.
Prescription therapy, by referral — These carry FDA-approved indications for menopausal vaginal atrophy and moderate to severe painful sex, the symptoms grouped under genitourinary syndrome of menopause. Their labels carry boxed warnings, which the prescriber goes through before anything is written. Written by your gynecologist or another prescriber, not here. Where the diagnosis is genitourinary syndrome of menopause, this is the route with an approved indication behind it.
Energy-based devices (fractional CO2 laser, Er:YAG laser, radiofrequency energy device) — No energy-based device is FDA-cleared or approved for vaginal rejuvenation, although some are cleared for unrelated gynecologic surgical uses. The FDA issued a safety communication in 2018 describing reports of vaginal burns, scarring and chronic pain. No such device is in use at Rouge Aesthetics.
The provider examines, takes a gynecologic history, and confirms screening.
Each option, with its regulatory status and price. A referral is explained, with the reason.
Blood drawn and spun while anesthetic sits 20 minutes. Injection to the anterior vaginal wall.
Ask when your result should be reviewed and what follow-up arrangements apply.
45 to 60 minutes, private room, chaperone offered and easily declined. Some visits end in a referral rather than an injection. That is ordinary.
The mechanism is a healing response over weeks. Patients who report a difference describe it at week 4 to 12. Those studies are small and mostly uncontrolled, and no duration is established.
No. The regulatory answer sits differently for each treatment the term covers. The U.S. Food and Drug Administration has not cleared or approved any energy-based device for vaginal rejuvenation, and it issued a safety communication in 2018 after reports of vaginal burns, scarring and chronic pain. Platelet injection for this purpose is also not FDA-approved. Prescription therapies for menopausal vaginal atrophy do carry approved indications, so those three sit in different regulatory positions and are worth keeping apart when they are compared.
The evidence does not settle it. Published studies of platelet-rich plasma for female sexual function and stress incontinence are small, uncontrolled and short. A pattern cannot be separated from time or expectation. Some report a difference; some none.
No vaginal energy-based device is FDA-cleared to treat urinary incontinence, and the FDA named incontinence specifically in its 2018 communication. Stress leaking usually comes from pelvic floor support rather than the surface of the vaginal wall. Pelvic floor physical therapy carries the largest evidence base for it, and the referral is to urogynecology.
The cost depends on your treatment plan. Call (614) 425-1633 for current pricing and ask what consultation, treatment, and follow-up charges apply.
Most patients describe pressure rather than sharp pain. Topical anesthetic sits 20 minutes, then buffered lidocaine; the injection takes a few minutes. Soreness and spotting for a day or two. Existing pain or vulvodynia is assessed first.
Wait 48 hours, or longer if the provider says so. Tampons, baths, pools and hot tubs wait the same 48 hours; showers are fine. Spotting and pressure in the first 24 to 48 hours are expected.
Not for genitourinary syndrome of menopause. Vaginal estrogen and prasterone, both vaginal inserts, and ospemifene, an oral tablet, carry FDA-approved indications for menopausal vaginal atrophy and painful sex, along with the largest evidence base and boxed warnings on their labels, which the prescriber goes through with you. Platelet injection has neither the approval nor that evidence. Where that route is closed, including after some breast cancers, the decision belongs with the treating oncologist.
Usually, yes. Tissue keeps changing for months after delivery, so treating early can mean paying for what time would do anyway. A postpartum evaluation and pelvic floor therapy come first. You are welcome to be examined meanwhile.
No. Labiaplasty is surgery that removes or reshapes labial tissue, performed by a surgeon under anesthesia. Nothing on this page cuts tissue. Length or protrusion of the labia minora is a surgical referral.
No one outside the room. Reminders and statements read Rouge Aesthetics with no treatment named. Nothing here is photographed, and no anatomical imagery appears on this site. A platelet injection adds no volume; there is nothing to see.
Vaginal rejuvenation is not a single procedure. No energy-based device is cleared or approved by the U.S. Food and Drug Administration for vaginal rejuvenation, and the FDA issued a safety communication on that marketing in 2018. Platelet-rich plasma and platelet-rich fibrin used in this region are unapproved uses of an autologous preparation, and hyaluronic acid placed in the labia majora is an off-label use of an approved filler.
Individual results vary. Nothing on this page promises a change in sensation, function, continence or appearance, and no treatment described here is a cure. Some patients report no change at all.
Juvéderm® and Restylane® are registered trademarks of Allergan Aesthetics and Galderma respectively. Rouge Aesthetics is not affiliated with or endorsed by those companies and names the products only to identify what is used.
This page is general information, not medical advice. Treatment requires an in-person examination and a medical eligibility review, and treatment is provided only where it is indicated.
Rouge Aesthetics · 101 Mill Street, Suite 210, Gahanna, OH 43230 · (614) 425-1633
Individual results vary. This website provides general information and does not replace an individual consultation.